A new analysis of health technology startups reveals that product innovation and clinical merit alone are insufficient to bring digital health solutions to patients. Instead, startups that secure access to data, healthcare institutions, and funding through deliberate partnership strategies reach market faster and scale more effectively than those relying solely on technology development.
Research from Kaunas University of Technology found that success in digital health depends not on the volume of partners a startup accumulates, but on the strategic value those partners bring. Healthcare remains uniquely constrained by regulation, limited customer bases, and fragmented data ownership-conditions that make collaboration not optional but essential for any startup attempting to move from prototype to clinical deployment.
“The health market is unique because it is heavily regulated, while the choice of customers is very limited. Although healthcare is highly innovation-driven, opportunities to commercialize these innovations are often constrained,” said Professor Asta Pundzienė from the School of Economics and Business at Kaunas University. The finding challenges conventional startup mythology, which often emphasizes founder vision and first-mover advantage in isolation.
Open Innovation as Ecosystem Requirement
The research makes clear that it is practically impossible for a health technology startup to develop, test, and commercialize an innovation independently. Instead, success hinges on what researchers call “open innovation”-a model in which multiple ecosystem participants co-create solutions and share in resulting revenues.
Startups seeking partners should identify so-called “gatekeepers” within their ecosystem-actors who maintain connections to many other players in healthcare infrastructure, data provision, regulatory expertise, and clinical validation. However, access alone is insufficient. The startup must possess the organizational capacity to translate partner resources into tangible product development and clinical evidence.
The distinction matters because many early-stage health companies gain formal partnerships without capturing actionable value. A data partnership means nothing if the startup lacks the data science infrastructure to use it. Institutional partnerships add little if the startup cannot navigate regulatory requirements or clinical workflows. The critical skill is converting partner relationships into integrated capabilities.
This finding aligns with emerging practice in the sector. Arizona’s Partnership for Economic Innovation has funded six health technology projects through Applied Research Centers partnered with Arizona State University, the University of Arizona, and Mayo Clinic College of Medicine and Science. Each project receives independent research validation and structured de-risking support. The model recognizes that early-stage medtech development requires institutional infrastructure, not just capital.
Data Access and Clinical Validation Drive Market Entry
Three resources consistently emerge as bottlenecks for health tech startups: clinical data, healthcare organization relationships, and development funding. Startups cannot access patient data without institutional intermediaries. They cannot test solutions at scale without hospital or clinic partnerships. They cannot navigate FDA pathways or health system procurement without regulatory and operational expertise embedded in their partner network.
Prickly Pear Health, a startup developing AI-powered voice journaling for women’s perimenopause health, illustrates this principle. The company’s founder noted that the Arizona funding partnership “gives us a runway to move faster, and the PEI Applied Research Centers has the connections to do it right.” The startup gained not just capital but validated connections to academic medical centers and research infrastructure necessary to move an AI consumer app toward clinical evidence standards.
Remote patient monitoring systems show similar patterns. AI-enabled systems that track physiological data in real time require integration with electronic health records, mobile platforms, cloud infrastructure, and clinical workflows. A startup building monitoring algorithms cannot succeed without partnerships that provide data to train models, healthcare systems to pilot implementations, and regulatory expertise to guide FDA submissions. The technical problem is inseparable from the ecosystem problem.
Revenue Sharing as Partnership Sustainability
A often-overlooked element of successful health tech partnerships is revenue alignment. Open innovation models that work long-term require partners to share in the value created, not merely provide resources upfront. This changes partner incentives from transactional (provide data, receive payment) to aligned (contribute resources, participate in upside).
Startups should structure partnerships as equity or revenue-share arrangements when possible, rather than pure vendor or licensing deals. This approach keeps partners invested in the startup’s success beyond the initial development phase and creates mutual accountability for market outcomes. It also signals to ecosystem participants that the startup is serious about long-term collaboration rather than extracting value and moving on.
The practical implication is that founders evaluating potential partners should assess not just what resources a partner controls, but whether partnership terms create sustained incentive alignment. A healthcare system or data provider willing to accept equity upside or revenue sharing may be more valuable than one offering cheaper data access without long-term commitment.
What Startups Must Build Beyond Technology
The research underscores that digital health success requires capabilities that venture capital and technical talent alone cannot supply. Startups need organizational competency in regulatory navigation, health system procurement, data governance, and clinical evidence generation. These competencies typically exist outside the startup and must be accessed through partnership.
For founders, the implication is clear: invest as heavily in partner identification and integration strategy as in product development. Map the ecosystem early. Identify which gatekeepers control access to data, clinical validation, and healthcare distribution. Negotiate partnerships that grant not just access but the ability to integrate partner resources into organizational capability. Structure long-term incentive alignment through revenue or equity sharing.
The startups that will reach market fastest and scale most effectively are those that view the healthcare ecosystem not as an obstacle to overcome but as a resource to absorb. The good idea is the entry point; the partnership strategy is the engine that drives it to patients.
